NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC lowered its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 45.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 855,688 shares of the medical research company's stock after selling 701,749 shares during the quarter. Emerald Advisers LLC owned approximately 0.67% of NeoGenomics worth $8,120,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Loomis Sayles & Co. L P raised its stake in shares of NeoGenomics by 48.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,791,792 shares of the medical research company's stock worth $29,528,000 after purchasing an additional 584,502 shares during the last quarter. Norges Bank purchased a new stake in shares of NeoGenomics during the fourth quarter worth approximately $6,273,000. Greenhouse Funds LLLP raised its stake in shares of NeoGenomics by 5.3% during the fourth quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock worth $77,487,000 after purchasing an additional 237,491 shares during the last quarter. Segall Bryant & Hamill LLC raised its stake in shares of NeoGenomics by 11.6% during the fourth quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company's stock worth $34,836,000 after purchasing an additional 220,415 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of NeoGenomics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company's stock worth $234,673,000 after purchasing an additional 195,793 shares during the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.

Insider Buying and Selling

In related news, COO Warren Stone bought 5,700 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average cost of $8.58 per share, for a total transaction of $48,906.00. Following the acquisition, the chief operating officer owned 108,280 shares in the company, valued at $929,042.40. This represents a 5.56% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lynn A. Tetrault bought 7,000 shares of the company's stock in a transaction that occurred on Friday, May 9th. The shares were bought at an average price of $8.14 per share, for a total transaction of $56,980.00. Following the completion of the acquisition, the director owned 7,000 shares in the company, valued at approximately $56,980. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 70,600 shares of company stock worth $550,438. Corporate insiders own 2.40% of the company's stock.

NeoGenomics Trading Down 0.6%

Shares of NeoGenomics stock traded down $0.05 during trading hours on Monday, reaching $7.21. The stock had a trading volume of 278,926 shares, compared to its average volume of 1,301,665. The firm has a 50 day simple moving average of $7.51 and a two-hundred day simple moving average of $10.29. The firm has a market capitalization of $928.41 million, a price-to-earnings ratio of -11.83 and a beta of 1.63. The company has a current ratio of 2.05, a quick ratio of 1.95 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a 1 year low of $6.08 and a 1 year high of $19.12.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). The firm had revenue of $168.04 million during the quarter, compared to analysts' expectations of $171.38 million. NeoGenomics had a negative return on equity of 2.21% and a negative net margin of 11.54%. The business's revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.02) earnings per share. As a group, equities research analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on NEO. Piper Sandler set a $12.00 price objective on NeoGenomics and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Guggenheim started coverage on NeoGenomics in a report on Thursday, May 15th. They issued a "neutral" rating on the stock. The Goldman Sachs Group decreased their price objective on NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Needham & Company LLC decreased their price objective on NeoGenomics from $18.00 to $8.50 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Finally, Morgan Stanley decreased their price objective on NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $13.83.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.